INCB001158 not checked
Incyte Corporation · CB-1158
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with…”In the company’s words, NCT03837509 on ClinicalTrials.gov
- Tested for
- Colorectal Cancer (CRC) (2 trials), Solid Tumors (2 trials), Relapsed or Refractory Multiple Myeloma, Biliary Tract Cancer (BTC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Metastatic Cancer and 9 more
- Main trialPhase 1/2
- “The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.”In the company’s words, NCT03837509 on ClinicalTrials.gov
- Other names
- CB-1158 · Arginase inhibitor
Other drugs for Colorectal Cancer (CRC)
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 5 Apr 2022 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | |
| Phase 1/2Completed | 28 Nov 2022 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | |
| Phase 1Completed | 30 Apr 2020 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | |
| Phase 1Completed | 14 Dec 2021 | A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026